Tau Pipeline Enabling Program V (T-PEP)
This grant funds translational research advancing therapies for tauopathies like Alzheimer's, focusing on moving promising candidates toward clinical development and human trials.
Funder: Alzheimer's Association
Due Dates: May 28, 2026 (Letter of Intent) | August 14, 2026 (Full application)
Funding Amounts: Up to $750,000 total for up to 2 years; nonprofits may request up to 10% indirect costs, none for for-profits.
Summary: Supports translational research advancing therapies for tauopathies, focusing on moving promising candidates toward clinical development for diseases like Alzheimer's, PSP, and FTD.
Key Information: Letter of Intent required; only invited applicants may submit full proposals.
Description
The Tau Pipeline Enabling Program V (T-PEP) is designed to accelerate the development of disease-modifying therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). The program specifically funds translational projects that focus on development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies for tau or tau-related mechanisms. The aim is to bridge the gap between innovative academic or small-company research and the resources needed to progress promising therapeutic candidates into human trials. Projects focused on compound or target discovery are not eligible; instead, the emphasis is on advancing existing candidates or strategies toward clinical readiness.
